Anti-cancer therapy made easier: a 25-year update.


Journal

Internal medicine journal
ISSN: 1445-5994
Titre abrégé: Intern Med J
Pays: Australia
ID NLM: 101092952

Informations de publication

Date de publication:
Apr 2021
Historique:
revised: 22 03 2020
received: 16 01 2020
accepted: 27 03 2020
pubmed: 4 5 2020
medline: 1 6 2021
entrez: 4 5 2020
Statut: ppublish

Résumé

In 1993, the Internal Medicine Journal published 'Chemotherapy made easier', outlining developments in supportive care of patients undergoing chemotherapy. This described the contemporary state of anti-emetics, colony stimulating factors, cardiac toxicity, neurotoxicity, development of drug analogues and venous access devices. Twenty-five years later, we update the measures that improve the tolerability of the plethora of new anti-cancer therapies, which have extended well beyond traditional chemotherapy agents to include immunotherapy and targeted therapies. Optimisation of supportive care is paramount to allow safe delivery with the least possible impact on quality of life of these new treatments, many of which have resulted dramatically improved outcomes across multiple cancer types. This state of the art update summarises advances in supportive care therapies relating to improving the patient experience during and after anti-cancer treatment, including new anti-emetics, hair preservation techniques, bone marrow support and improved venous access devices; the ongoing challenge of neurotoxicity; and the advent of multidisciplinary sub-specialised fields such as cardio-oncology and oncofertility. Supportive care medications for immuno-oncology therapies is a new section; these highly effective (although not universally so) agents were a mere illusion in 1993.

Identifiants

pubmed: 32362017
doi: 10.1111/imj.14878
pmc: PMC8251731
doi:

Substances chimiques

Antineoplastic Agents 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

473-480

Informations de copyright

© 2020 The Authors. Internal Medicine Journal by Wiley Publishing Asia Pty Ltd on behalf of Royal Australasian College of Physicians.

Références

J Thorac Dis. 2018 Dec;10(Suppl 35):S4351-S4366
pubmed: 30701103
Int J Cancer. 2015 Mar 1;136(5):E442-54
pubmed: 25081068
Oncol Rev. 2017 Jul 18;11(2):340
pubmed: 28781723
Ann Oncol. 2017 Jun 1;28(6):1260-1267
pubmed: 28398530
JAMA. 2017 Feb 14;317(6):596-605
pubmed: 28196254
Psychooncology. 2010 Jul;19(7):701-9
pubmed: 19637250
J Am Coll Cardiol. 2019 Jun 11;73(22):2859-2868
pubmed: 31171092
Ann Oncol. 2017 Jul 1;28(suppl_4):iv119-iv142
pubmed: 28881921
Ann Oncol. 2014 Jul;25(7):1333-1339
pubmed: 24631949
Cochrane Database Syst Rev. 2018 Jul 30;7:CD008462
pubmed: 30058070
J Clin Oncol. 2019 May 20;37(15):1336-1351
pubmed: 30969847
Lancet. 2017 Mar 25;389(10075):1195-1205
pubmed: 28215665
Br J Haematol. 2016 Aug;174(4):563-70
pubmed: 27072050
Am Soc Clin Oncol Educ Book. 2018 May 23;38:27-37
pubmed: 30231357
Ultrasound Obstet Gynecol. 2018 Jan;51(1):77-86
pubmed: 29055060
N Engl J Med. 2018 Mar 29;378(13):1177-1188
pubmed: 29590544
Clin Ther. 2016 Jul;38(7):1551-66
pubmed: 27158009
Support Care Cancer. 2016 May;24(5):1941-1954
pubmed: 26476625
Lancet Oncol. 2013 Feb;14(2):e50-9
pubmed: 23369683
Breast Cancer Res Treat. 2017 Jun;163(2):199-205
pubmed: 28275922
Aust N Z J Med. 1993 Aug;23(4):387-92
pubmed: 8240152
Hum Reprod. 2016 Sep;31(9):2031-41
pubmed: 27378768
J Clin Oncol. 2002 Mar 1;20(5):1215-21
pubmed: 11870163
Pain. 2014 Dec;155(12):2461-2470
pubmed: 25261162
Breast Cancer Res Treat. 2019 Sep;177(2):237-250
pubmed: 31165940
Oncologist. 2020 Mar;25(3):229-234
pubmed: 32162828
Eur J Cancer. 2018 Jan;89:49-55
pubmed: 29227817
Ann Oncol. 2014 Jul;25(7):1328-1333
pubmed: 24603643
N Engl J Med. 2016 Jul 14;375(2):134-42
pubmed: 27410922
Acta Oncol. 2019 Apr;58(4):398-406
pubmed: 30638100
Ann Oncol. 2019 Apr 1;30(4):582-588
pubmed: 30715153
JAMA. 2013 Apr 3;309(13):1359-67
pubmed: 23549581

Auteurs

Amy Davies (A)

Department of Oncology, Monash Health, Melbourne, Victoria, Australia.

Caroline Lum (C)

Department of Oncology, Monash Health, Melbourne, Victoria, Australia.

Rachel Raju (R)

Department of Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

Evan Ansell (E)

Department of Oncology, Monash Health, Melbourne, Victoria, Australia.

Kate Webber (K)

Department of Oncology, Monash Health, Melbourne, Victoria, Australia.
School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia.

Eva Segelov (E)

Department of Oncology, Monash Health, Melbourne, Victoria, Australia.
School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH